94 results on '"Gerber, David E."'
Search Results
2. Taking It to the States: Adapting Information Blocking Legislation to Oncology
3. Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?
4. Expanding the role of advanced practice providers (APPs) in cancer clinical trials.
5. Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC.
6. The role of experience and clinical decision support in clinical trial accrual within oncology.
7. Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.
8. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
9. Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy.
10. Thyroid dysfunction and immune checkpoint inhibitor outcomes.
11. Survival among breast cancer patients with a history of previous cancer.
12. Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.
13. Survival among colorectal cancer patients with a history of previous cancer.
14. Immune checkpoint inhibition-induced myocarditis in cancer patients: Proposal of a detection and management strategy.
15. Correlating immune toxicity, blood cell counts, and overall survival in cancer patients receiving immune therapy.
16. Preventable patient acute mortality after EMR-generated QTc alerts.
17. ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
18. Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
19. Conceptual Model for Accrual to Cancer Clinical Trials
20. Expression of soluble DC-HIL/gpnmb receptor in the blood of metastatic non-small cell lung carcinoma treated with anti-PD1/PDL1 monoclonal antibodies.
21. Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC).
22. Variation in the assessment of immune-related adverse event occurrence, grade, and timing.
23. Mobile device access to electronic patient portals in oncology: Potential implications for patient and practice experiences.
24. Use of QTc-prolonging medications among patients with lung cancer: implications for clinical trials and standard clinical care.
25. Underlying host immune dysregulation in cancer patients developing immune-related adverse events.
26. A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC.
27. Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients.
28. Phase 1 study of ARQ 761, a β-lapachone analog that promotes NQO1-mediated programmed cancer cell necrosis.
29. Treatment and outcomes of primary pericardial mesothelioma: A systematic review.
30. Randomized phase III trial of concurrent chemoradiation followed by nivolumab or placebo for locally advanced non-small cell lung cancer (NSCLC) (RTOG 3505).
31. Cancer center clinic and clinical research team perceptions of identity and interactions.
32. Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.
33. Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials.
34. Institutional scientific review of cancer clinical research protocols: Impact of requirement on activation timelines.
35. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.
36. Preliminary correlative analysis of PD-L1 expression from the SUNRISE study.
37. Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).
38. Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma
39. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
40. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
41. Prevalence of autoimmune conditions among patients with lung cancer: Implications for immunotherapy treatment options.
42. Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).
43. Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).
44. Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.
45. Development and use of a staffing model for clinical research teams at an NCI Comprehensive Cancer Center.
46. Effect of prior cancer on outcomes in early stage lung cancer: Implications for clinical trial eligibility and accrual.
47. Safety and tolerability of concurrent Nab-P (Nab-P) and Carbo (Carbo) with thoracic radiotherapy (RT) followed by consolidative Nab-P and Carbo in patients with stage IIIA/B non-small cell lung cancer (NSCLC).
48. Cancer center staff effort related to electronic patient portal use: A growing demand.
49. Antibody mediated blockade of phosphatidylserine to enhance immune checkpoint blockade by repolarizing immune suppressive mechanisms of the tumor microenvironment.
50. PPHM 1501- An open-label, randomized, phase II trial of durvalumab (MEDI4736) with or without bavituximab in patients with previously treated metastatic non-small cell lung cancer (NSCLC): Safety report on first 18 patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.